Kathryn A. Hanley

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

Attenuated dengue virus comprising mutations in the NS3 gene

Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3' untranslated region

Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis

Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein

Short Communication Replacement of conserved or variable sequences of the mosquito-borne dengue virus 39 UTR with homologous sequences from Modoc virus does not change infectivity for mosquitoes

Short Communication Replacement of the 39 untranslated variable region of mosquito-borne dengue virus with that of tick- borne Langat virus does not alter vector specificity

Dengue vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1 and 2.

Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2. Dengue vaccine containing a common 30 nucleotide deletion in the 3 'UTR of Dengue types 1 and 2. FIG.

Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.